Eisai - CPP Pediatric Doctor and Patient Family Needs Research
Company overview
Eisai Group is a global biopharmaceutical company headquartered in France, dedicated to drug innovation and in-depth research in oncology, neuroscience, and rare diseases. The company is committed to improving patients' quality of life through advanced therapeutic approaches. Among its products, Lupron is widely used in the treatment of central precocious puberty (CPP) and has become one of the preferred treatment options in this field, holding a significant position in pediatric endocrinology.
Research background
Central precocious puberty (CPP), especially central precocious puberty, has seen a gradual rise in incidence among children and has become one of the more common endocrine disorders in pediatric medicine, significantly impacting normal growth and development in children. The formulation choice of GnRHa drugs in the treatment of CPP directly influences treatment adherence and clinical outcomes. Eisai aims to gain deeper insights into the preferences, usage experiences, and unmet needs of doctors and patient families when choosing between 0-month and 3-month formulations, in order to refine product promotion strategies and enhance market responsiveness. Research Content In February 2021, CEIDEA Research was commissioned by Eisai Group to conduct a research project focused on the treatment of CPP. The study was carried out in two stages using a nationally representative sampling approach: the first stage involved in-depth interviews with pediatric endocrinology doctors to understand their preferences for different GnRHa formulations (1-month and 3-month), their prescribing criteria, and evaluation frameworks; the second stage involved qualitative interviews with parents of children receiving treatment with the 1-month formulation of Lupron, to gain a deeper understanding of their treatment experiences, adherence, satisfaction with outcomes, and actual benefits derived. Expected Outcomes The final research report will provide a comprehensive understanding of the decision-making logic of both doctors and patients in the treatment of CPP, systematically identifying key considerations in doctors' recommendations and challenges and concerns faced by parents during treatment. By conducting a deep analysis of the gap between current formulation acceptance and expectations, Eisai will be able to develop more targeted and forward-looking strategies in areas such as formulation optimization, product education, and promotional strategy development.
Scan to add our research consultant